April 17, 2025 ACE Inhibitors as a Cardioprotective Treatment in Dystrophinopathies ACE inhibitors were the first pharmacological class shown to benefit heart failure treatment...
March 13, 2025 Principles of good practice for translation of electronic clinical outcome assessments While many publications have outlined good practice recommendations for translation and electronic implementation of clinical...
March 10, 2025 C-Path’s Critical Path for Parkinson’s Consortium Welcomes CND Life Sciences C-Path is excited to welcome CND Life Sciences as the newest member of it Critical Path for Parkinson’s (CPP) Consortium. CND Li
New Biomarkers Could Improve Early Detection, Monitoring of Kidney Injury C-Path and Boston Medical Center published results for six biomarkers that could improve the early and accurate detection...
C-Path Announces Steven W. Spector and James A. King as New Board Members C-Path announced the appointments of Steven W. Spector and James A. King to its Board of Directors...
February 28, 2025 Ultra Rare: A Mission to Discover the Cause Behind a Young Boy’s Developmental Delays Kelly Carwile, mother to Reed and sister of C-Path Director Mike Minchik, has been on a mission to discover the cause behind her..
February 26, 2025 Transforming Data into Breakthroughs: 5 Years of RDCA-DAP Journey and Impact In honor of Rare Disease Month, Alexandre Bétourné took some time to sit down and discuss the impact RDCA-DAP has made...
January 14, 2025 Addressing the need for Standardization of Symptomatic Medication Documentation in Parkinson’s Disease Clinical Research: A Call to Action People with Parkinson's disease (PD) are prescribed a variety of medications to mitigate symptoms and improve their quality...
February 25, 2025 A Framework to Standardize Gait Study Protocols in Parkinson’s Disease Research over the past twenty years has shown that gait outcomes have a high sensitivity for diagnosing Parkinson's disease (PD)..
February 1, 2025 Understanding what aspects of Parkinson’s disease matter most to patients and families Understanding what matters to people with Parkinson’s and their family is essential to derive relevant clinical outcome measures